Ipsos Healthcare has launched its syndicated Pan-Cancer Testing Monitor (PCTM) in Australia. The service measures and tracks the use of tests designed for a wide range of cancer types to help doctors make more informed treatment decisions.
Running in the US since 2016, the PCTM gathers perceptions from medical oncologists and pathologists on topics such as awareness and current utilisation of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. It also incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test. The detailed information collected includes brand used, reason for testing, reasons for brand choice, treatment impact, test outcome and satisfaction with the test, among other data. Further expansion of the study to Asia-Pacific markets is planned for the coming months.
Pieter De Richter (pictured), Head of Syndicated Real World Evidence in APAC/MENA, comments: 'Pan-cancer testing is a rapidly growing, continually evolving and extremely dynamic market segment. With the launch of the study in Australia, we are now able to provide molecular diagnostics businesses and pharma companies with robust insights into drivers and barriers around the usage of pan-cancer testing panels and detailed usage metrics within this important region'.
Web site: www.ipsos.com .
All articles 2006-18 written and edited by Mel Crowther and/or Nick Thomas.